Furthermore, in bladder cancer patients receiving neoadjuvant platinum-based therapies, low/intermediate mRNA levels of BRCA1 were associated with increased tumor pathological response and overall survival (50), while DNA damage in normal breast epithelia of women with a BRCA mutation positively correlated with BMI and biomarkers of metabolic dysfunction (51). Here, BRCA1 is linked to neoplasm.